» Articles » PMID: 25987565

The Transmission Interfaces Contribute Asymmetrically to the Assembly and Activity of Human P-glycoprotein

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2015 May 20
PMID 25987565
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

P-glycoprotein (P-gp; ABCB1) is an ABC drug pump that protects us from toxic compounds. It is clinically important because it confers multidrug resistance. The homologous halves of P-gp each contain a transmembrane (TM) domain (TMD) with 6 TM segments followed by a nucleotide-binding domain (NBD). The drug- and ATP-binding sites reside at the interface between the TMDs and NBDs, respectively. Each NBD is connected to the TMDs by a transmission interface involving a pair of intracellular loops (ICLs) that form ball-and-socket joints. P-gp is different from CFTR (ABCC7) in that deleting NBD2 causes misprocessing of only P-gp. Therefore, NBD2 might be critical for stabilizing ICLs 2 and 3 that form a tetrahelix bundle at the NBD2 interface. Here we report that the NBD1 and NBD2 transmission interfaces in P-gp are asymmetric. Point mutations to 25 of 60 ICL2/ICL3 residues at the NBD2 transmission interface severely reduced P-gp assembly while changes to the equivalent residues in ICL1/ICL4 at the NBD1 interface had little effect. The hydrophobic nature at the transmission interfaces was also different. Mutation of Phe-1086 or Tyr-1087 to arginine at the NBD2 socket blocked activity or assembly while the equivalent mutations at the NBD1 socket had only modest effects. The results suggest that the NBD transmission interfaces are asymmetric. In contrast to the ICL2/3-NBD2 interface, the ICL1/4-NBD1 transmission interface is more hydrophilic and insensitive to mutations. Therefore the ICL2/3-NBD2 transmission interface forms a precise hydrophobic connection that acts as a linchpin for assembly and trafficking of P-gp.

Citing Articles

Systematic estimation of cystic fibrosis prevalence in Chinese and genetic spectrum comparison to Caucasians.

Ni Q, Chen X, Zhang P, Yang L, Lu Y, Xiao F Orphanet J Rare Dis. 2022; 17(1):129.

PMID: 35313924 PMC: 8935702. DOI: 10.1186/s13023-022-02279-9.


Theoretical insights on helix repacking as the origin of P-glycoprotein promiscuity.

Bonito C, Ferreira R, Ferreira M, Gillet J, Cordeiro M, Dos Santos D Sci Rep. 2020; 10(1):9823.

PMID: 32555203 PMC: 7300024. DOI: 10.1038/s41598-020-66587-5.


Replacing the eleven native tryptophans by directed evolution produces an active P-glycoprotein with site-specific, non-conservative substitutions.

Swartz D, Singh A, Sok N, Thomas J, Weber J, Urbatsch I Sci Rep. 2020; 10(1):3224.

PMID: 32081894 PMC: 7035247. DOI: 10.1038/s41598-020-59802-w.


Dynamics of ABC Transporter P-glycoprotein in Three Conformational States.

Kopcho N, Chang G, Komives E Sci Rep. 2019; 9(1):15092.

PMID: 31641149 PMC: 6805939. DOI: 10.1038/s41598-019-50578-2.


Conformational dynamics of P-glycoprotein in lipid nanodiscs and detergent micelles reveal complex motions on a wide time scale.

Li M, Guttman M, Atkins W J Biol Chem. 2018; 293(17):6297-6307.

PMID: 29511086 PMC: 5925813. DOI: 10.1074/jbc.RA118.002190.


References
1.
Loo T, Clarke D . Identification of residues in the drug-binding domain of human P-glycoprotein. Analysis of transmembrane segment 11 by cysteine-scanning mutagenesis and inhibition by dibromobimane. J Biol Chem. 1999; 274(50):35388-92. DOI: 10.1074/jbc.274.50.35388. View

2.
Dey S, Ramachandra M, Pastan I, Gottesman M, Ambudkar S . Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A. 1997; 94(20):10594-9. PMC: 23414. DOI: 10.1073/pnas.94.20.10594. View

3.
Omote H, Al-Shawi M . A novel electron paramagnetic resonance approach to determine the mechanism of drug transport by P-glycoprotein. J Biol Chem. 2002; 277(47):45688-94. DOI: 10.1074/jbc.M206479200. View

4.
Loo T, Bartlett M, Clarke D . Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J Biol Chem. 2003; 278(41):39706-10. DOI: 10.1074/jbc.M308559200. View

5.
Loo T, Bartlett M, Clarke D . Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains. J Biol Chem. 2004; 279(37):38395-401. DOI: 10.1074/jbc.M405623200. View